Home / Treatments / Cardiac Rx
Cardiac Rx denials: what the review data shows
Independent reviewers have decided 180 published cases where an insurer denied Cardiac Rx — and they overturned the insurer 38.9% of the time. A denial for Cardiac Rx is a starting position, not a final answer.
Published decisions
180
2001–2026
Overturned
38.9%
70 denials reversed
Conditions behind cardiac rx denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| High Cholesterol | 43 | 37.2% |
| Cardiac Heart Prob | 16 | 25% |
| Hypertension | 11 | 45.5% |
| CAD | 10 | 40% |
| Congestive Heart Failure | 9 | 33.3% |
| Coronary Artery Disease | 9 | 44.4% |
| Cardiomyopathy | 6 | 66.7% |
| Heart Attack | 5 | 60% |
| Arrhythmia Irregular Heart Rhythm | 4 | 50% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 171 | 38% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 9 | 55.6% |
Typical time to a decision
11 days
Most land between 5 and 21 days
Handled as urgent
44.4%
Expedited when a delay would cause harm
Recent direction
Falling
50% → 24.4% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The physician reviewer found in this patient’s case, the records document known vascular disease and severe hyperlipidemia with documented intolerance to several statin medications. Praluent is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor studied in and approved for patients with heterozygous familial hypercholesterolemia or for patients with documented atherosclerotic vascular disease who require additional lowering of low-density lipoprotein (LDL) cholesterol. This patient fits the latter criteria. PCSK9 inhibitors have been demonstrated to be effective at lowering LDL cholesterol and are associated with improved cardiovascular outcomes in this setting. In addition, treatment with ezetimibe in this setting would not be expected to result in LDL reduction near the recommended goal reduction required in this patient.
Nature of Statutory Criteria/Case Summary: The patient has been diagnosed with atherosclerotic heart disease of native coronary artery without angina. The patient was noted to be taking Zetia 10 mg and simvastatin 10 mg. The provider noted the patient’s low-density lipoprotein (LDL) level increased to 110 mg/dl while taking Zetia. The patient reported intermittent pain with exertion. His diagnoses included hypertension and hyperlipidemia. The patient’s low-density lipoprotein (LDL) cholesterol level was 174 mg/dl. In the Health Plan Prescription Drug Prior Authorization or Step Therapy Exception Request Form, the provider noted the patient had tried and failed Zetia, simvastatin, and atorvastatin. The documentation noted that simvastatin caused leg pain. The patient also been treated with stent procedures.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for Prolia (denosumab) subcutaneous injections. Osteoporosis is one of the most frequent diseases in postmenopausal women, leading to an increased fracture risk due to the physiologic loss of the bone protective effects of estrogen. Joint guidelines by the International Osteoporosis Foundation (IOF) recommend the use of dual energy x-ray absorptiometry (DEXA) screening early in the evaluation of bone health for patients with breast cancer. The IOF guidelines further recommend that antiresorptive therapy should be considered in all patients with a bone mineral density (BMD) T-score less than -2.0 or two risk factors including a BMD T-score less than -1.0.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Nexletol. Bempedoic acid has demonstrated efficacy in lowering LDL-cholesterol (LDL-C) as both monotherapy and in combination with ezetimibe. A fixed-dose combination of bempedoic acid and ezetimibe reduces LDL-C by approximately 40%, which is comparable to two-thirds the amount of LDL-C lowering typically achieved with proprotein convertase subtilisin–kexin type (PCSK9) inhibitors. Bempedoic acid offers the potential for further LDL-C lowering in statin-intolerant patients or in those requiring further LDL-C reduction despite maximally tolerated statin therapy. The U.S.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Cardiac Rxwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.